NuVasive 2Q Earnings Surge Despite Sector Concerns

Date : 07/27/2010 @ 6:23PM
Source : Dow Jones News
Stock : Nuvasive, Inc. (MM) (NUVA)
Quote : 54.25  -0.36 (-0.66%) @ 5:50PM

NuVasive 2Q Earnings Surge Despite Sector Concerns

Nuvasive (NASDAQ:NUVA)
Historical Stock Chart

5 Years : From Sep 2012 to Sep 2017

Click Here for more Nuvasive Charts.

NuVasive Inc.'s (NUVA) second-quarter earnings more than doubled behind surging sales as the maker of devices for spinal-fusion surgery continued to shake off challenging market conditions seen by competitors.

The San Diego-based company boosted its full-year earnings guidance Tuesday, raised the lower end of its sales forecast and maintained its outlook for sales growth next year. Shares rose 2.8%, to $35.00 in after-hours trading.

Reports last week from Johnson & Johnson (JNJ) and Stryker Corp. (SYK) added to signs the $8 billion to $9 billion spinal-device market is facing pressure on product prices and procedure volumes that is restraining growth. But NuVasive, which markets tools for a unique procedure the company says cuts blood loss and hospital stays, has managed to maintain its high-growth pace by taking market share.

NuVasive posted second-quarter earnings of $6.7 million, or 17 cents per share, up from $2.8 million, or 7 cents, a year ago. Excluding stock-based compensation and other costs, it said earnings were 42 cents in the recent quarter.

Sales rose 35%, to $119.6 million. Analysts surveyed by Thomson Reuters had forecast, on average, earnings of 29 cents a share on sales of $117.7 million.

Looking ahead, the company said it now expects full-year sales of $485 million to $500 million, with the bottom end of that range up $5 million from the prior forecast. It forecast earnings excluding items of $1.50 to $1.64 per share, compared with the prior $1.13 to $1.25 per share forecast.

Analysts had forecast full-year earnings of $1.21 per share on sales of $490.3 million.

Alex Lukianov, NuVasive's chairman and chief executive, said on a conference call that the company continues to expect sales growth of 25% to 30% next year. He also said, as he has before, that product innovations could fuel faster growth.

-By Jon Kamp, Dow Jones Newswires; 617-654-6728; jon.kamp@dowjones.com

 
 

Latest NUVA Messages

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts


Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.


NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.